This website uses technical, customisation and analytical cookies, both first-party and third-party, to anonymously facilitate browsing and analyse statistics on use of the website. Learn more
Search results
-
Pfizer and the Challenges of the Pharmaceutical Industry (A)
Renate Kratochvil; Phillip C. NellCase IVEY-9B19M076-EStrategyIn 2018, President of the United States, Donald Trump, criticized the company Pfizer Inc. (Pfizer) for increasing drug prices—which had been a strategic move by Pfizer in response to industry-wide challenges. This announcement highlighted the complex dynaStarting at €8.20
-
Pfizer and the Challenges of the Pharmaceutical Industry (A) - Teaching Note
Renate Kratochvil; Phillip C. NellTeaching Note IVEY-8B19M076-EStrategyTeaching note for product 9B19M076.Starting at €0.00
-
Pfizer and the Challenges of the Pharmaceutical Industry (B) - Teaching Note
Renate Kratochvil; Phillip C. NellTeaching Note IVEY-8B19M077-EStrategyTeaching Note to accompany product 9B19M077.Starting at €0.00
-
Pfizer and the Challenges of the Pharmaceutical Industry (B)
Renate Kratochvil; Phillip C. NellCase IVEY-9B19M077-EStrategyCase B complements Case A, describing pharmaceutical companies’ strategic responses—such as mega-mergers and acquisitions and specialization—to industry-wide global challenges and highlights strategic decisions by Pfizer’s chief executive officers betweenStarting at €5.74
-
Managing a Severe Crisis: PharmaCorp in Ukraine
Phillip C. Nell; Renate Kratochvil; Patricia KlopfCase IVEY-9B17M085-EStrategyIn early 2015, the newly appointed country head of PharmaCorp’s operating unit in Ukraine faced internal and external challenges in managing the global pharmaceutical company’s operations in the crisis-ridden country. Since November 2013, Ukraine had undergone massive disruptions, including riots in Kiev, the annexation of Crimea by Russia, and a war in its easternmost region. Amid these economic and political turbulences, PharmaCorp Ukraine expe...Starting at €8.20